Transplant drug two-year study outcomes show superior kidney function

Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.

Read the whole article on Science Daily

More from Science Daily